Format

Send to

Choose Destination
Allergy. 2015 Aug;70(8):887-96. doi: 10.1111/all.12632. Epub 2015 May 20.

Past, present, and future for biologic intervention in atopic dermatitis.

Author information

1
MedImmune, LLC, Gaithersburg, MD, USA.

Abstract

Atopic dermatitis (AD) is a debilitating disease that significantly alters the quality of life for one in four children and one in 10 adults. Current management of AD utilizes combinations of treatments to symptomatically alleviate disease by suppressing the inflammatory response and restoring barrier function in the skin, reducing disease exacerbation and flare, and preventing secondary skin infections. Resolution is temporary and long-term usage of these treatments can be associated with significant side-effects. Antibody therapies previously approved for inflammatory diseases have been opportunistically evaluated in patients with atopic dermatitis; however, they often failed to demonstrate a significant clinical benefit. Monoclonal antibodies currently in development offer hope to those individuals suffering from the disease by specifically targeting immune and molecular pathways important for the pathogenesis of atopic dermatitis. Here, we review the underlying biological pathways and the state of the art in therapeutics in AD.

KEYWORDS:

atopic dermatitis; basic mechanisms; clinical immunology; dermatology; quality of life

PMID:
25879391
DOI:
10.1111/all.12632
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center